FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely to therapy and neurology, and concerns treating vertigos of various origins. That is ensured by administering a pharmaceutical composition containing an activated potentiated form of anti-brain specific protein S-100 antibodies and an activated potentiated form of anti-endothelial NO-synthase antibodies.
EFFECT: administering this composition provides the effective treatment of vertigos by synergetic action of the ingredients of the composition.
10 cl, 13 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING VEGETATIVE-VASCULAR DYSTONIA AND MEDICINAL PRODUCT | 2013 |
|
RU2577130C2 |
| ANTI-PD-L1 ANTIBODY FOR PD-L1 DETECTION | 2018 |
|
RU2758723C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
